Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+10.5%
EPS
+9.35%
Free cash flow
+51.8%
Total debt
+18.7%

Quarter to June 2026, against a year earlier

697.00 12.18 −1.72%
Market cap
$262.2B
P/E
37.4×
Fwd P/E
35.7×
Dividend yield
0.26%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100

Thermo Fisher Scientific Inc. (TMO) revenue by segment, product and region

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.